TOKYO — German drugmaker Boehringer Ingelheim plans to invest a total of 300 million euros ($346 million) in its plant in Japan from 2023 to 2028 as it moves to make the facility a production base for Asia and Oceania.
The plant, in the country’s northeastern prefecture of Yamagata, currently produces the diabetes and kidney disease treatment drug Jardiance, mainly for the domestic market.
AloJapan.com